Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.503
-0.006 (-1.24%)
Nov 22, 2024, 4:00 PM EST - Market closed
Windtree Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
4.40M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionWINT News
- 4 weeks ago - Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewsWire
- 5 weeks ago - Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - GlobeNewsWire
- 7 weeks ago - Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock - GlobeNewsWire
- 2 months ago - Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET - GlobeNewsWire
- 2 months ago - Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock - GlobeNewsWire
- 3 months ago - Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 3 months ago - Windtree Announces New Additions and Changes to Its Board of Directors - GlobeNewsWire
- 4 months ago - Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - GlobeNewsWire